Executive Leadership

John H. Tucker is the chief executive officer of scPharmaceuticals. Prior to scPharmaceuticals, Mr. Tucker served as chief executive officer of Algal Scientific, a developer of auto-immune products. There he repositioned the company and successfully negotiated its sale. Prior to Algal, he served as chief executive officer at Alcresta, a developer of enzyme-based products for patients with acute and chronic diseases. While at Alcresta he led regulatory and financing strategies leading to its first product approval and increased valuation. Prior to Alcresta, he served as senior vice president and chief commercial officer of Incline Therapeutics, a hospital-focused specialty pharmaceutical company. There, he developed and drove the overall commercial strategy in support of the company’s lead product, IONSYS™, resulting in a $390 million purchase of Incline by The Medicines Company. He joined Incline from AMAG Pharmaceuticals, where he was senior vice president, commercial operations, responsible for all sales and marketing activities for the company. Previously, as president, U.S. operations at Basilea Pharmaceuticals, Mr. Tucker developed the strategy and organization for the planned launch of a hospital-focused product and led the company’s commercial development team. Prior to Basilea, Mr. Tucker was executive vice president, sales and marketing at Indevus Pharmaceuticals. Earlier in his career, he held a variety of both hospital and retail-based sales and marketing positions with increasing levels of responsibility at Ortho-McNeil Pharmaceuticals, ALZA Corporation, VIVUS and UCB Pharma. Mr. Tucker holds a B.A. from Plymouth State College and an MBA from New Hampshire College.

Rachael serves as scPharmaceuticals’ Chief Financial Officer, responsible for all financial operations including external reporting, corporate accounting and internal controls. She is a senior financial executive with more than 20 years of experience, primarily in the life science industry. Rachael joined scPharmaceuticals in 2014 from BG Medicine, Inc., a publicly traded medical device company, where she was Director of Accounting. At BG Medicine, Ms. Nokes had significant responsibilities related to securing and managing several rounds of financing from various venture capital and other funding sources, culminating in the company’s initial public offering in early 2011. She was also instrumental in transitioning the finance organization from a privately held model to one capable of meeting the requirements for publicly traded entities, including SEC reporting and the implementation of Sarbanes Oxley. Prior to BG Medicine, Rachael held positions within Oak Industries, Inc., a publicly traded supplier of components to the communications industry, and PriceWaterhouseCoopers, where she began her career as an auditor. She received a B.S. in Accounting from the Carroll School of Management at Boston College and an M.S. in Finance from Bentley University.

Mike serves as scPharmaceuticals’ Senior Vice President of Technical Operations where he is responsible for overall product development, supply chain and quality. Mike entered the medical device field after serving in the U.S. Army, and for the past 25 years he has held various positions of increasing responsibility in manufacturing and product development with both contract manufacturing and OEM medical device companies. Mike has significant experience leading manufacturing and product development teams in multiple settings, including large publicly traded multinational organizations like Stryker and Smith & Nephew, and startup operations, from early product development through manufacturing scale and eventual acquisition. Most recently, Mike led operations as Chief Operating Officer for CeQur Corporation, an early stage medical device company developing a wearable insulin infusion device. Mike holds a B.S. degree in Mechanical Engineering from the United States Military Academy at West Point.

Dr. Mohr is a pharmacist with 20 years of experience as a clinician, researcher, teacher, scientist and medical affairs leader. He began his career in clinical practice at Memorial Hermann Hospital and held the role of Assistant Professor of Medicine at the University of Texas Medical School in Houston from 2003-2007. In addition to his clinical responsibilities in the hospital, he served as an investigator for multiple phase 3 and 4 clinical trials and conducted research focused on the pharmacokinetics and pharmacodynamics of antibiotics. Dr. Mohr began his career in the pharmaceutical industry at Cubist Pharmaceuticals where he had multiple roles to support the commercialization of Cubicin within the Medical Affairs function, serving as a field medical affairs liaison and ultimately leading the medical affairs strategy group. In addition, he supported the medical affairs integration of two companies (Adalor and Optimer) upon acquisition and led the medical affairs launch of Zerbaxa and Sivextro until Cubist was acquired by Merck for $9.5 billion. Following his tenure at Cubist Pharmaceuticals, John served as Vice President of Medical Affairs at the Medicines Company where he led the medical affairs strategy for Orbactiv and Minocin IV, and as Vice President of Medical Affairs at Tetraphase, where he managed building out the medical affairs function to support the launch of Xerava. Dr. Mohr received his B.S. in Biomedical Sciences from Texas A&M University and his Pharm.D. from the University of Houston College of Pharmacy.